HUTCHMED (China) Ltd
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 27.3
- Dividend yield
- –
About HUTCHMED (China)
Pharmaceutical Preparations, SIC 2834
HUTCHMED (China) Limited is a commercial-stage biopharmaceutical company engaged in discovering, developing, and commercializing targeted therapies and immunotherapies. Its research and clinical development pipeline targets patients with various cancers and immunological diseases. The enterprise operates across novel oncology and immunology therapies alongside another venture focused on the marketing and distribution of prescription drugs and healthcare products. Key approved treatments include fruquintinib, savolitinib, and surufatinib, alongside licensed therapies like tazemetostat. The company distributes its medicines directly and collaborates with global pharmaceutical partners to deliver therapies to patients worldwide.
The enterprise maintains global drug development operations and clinical trials, with commercial authorization for its treatments spanning dozens of countries, including China, the United States, Japan, and several European nations. It operates three drug product manufacturing sites situated in Suzhou, Shanghai, and Switzerland, supported by research teams and a domestic oncology commercial sales force. Corporate headquarters are located in Hong Kong, with an additional registered corporate office in the Cayman Islands.
Summary of the business section of HUTCHMED (China)'s latest annual report, written by StockData.
Company profile
Company
- Legal name
- HUTCHMED (China) Ltd
- Founded
- 2000
- Headquarters
- Hong Kong, Hong Kong
- Address
- 48th Floor, Cheung Kong Center, 2 Queen'S Road Central
- Phone
- 852-2121-3888
- Website
- hutch-med.com
- Employees
- 109, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- E9
- Auditor
- PricewaterhouseCoopers Zhong Tian LLP, Shenzhen, the Peoples Republic of China
Stock & identifiers
- Ticker
- HCM
- Other tickers
- HMDCF
- Exchange
- Nasdaq
- IPO date
- Mar 18, 2016
- Shares outstanding
- 872M, Dec 31, 2025
- Filer category
- Large accelerated filer
- Stock splits
- 10-for-1, May 30, 2019; 10-for-1, May 30, 2019
- SEC CIK
- 1648257
- CUSIP
- 44842L103
- ISIN
- US44842L1035
- LEI
- 2138006X34YDQ6OBYE79
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Chig Fung Cheng | Acting CEO and CFO, Director | 56,693 |
| Wei-guo Su | CEO and CSO, Director | 3,563,905 |
| Charles George Rupert Nixon | Group General Counsel | 41,763 |
| Lorenso Chiu | Deputy Chief Financial Officer | 8,475 |
| Renu Bhatia | Director | 16,000 |
| Ling Yang | Director | – |
| Tak Wai Wong | Director | – |
| Daniel Shao Weng Tan | Director | – |
| Dan Eldar | Director | 19,000 |
| Chaohong Hu | Director | – |
| Edith Shih | Director | 100,000 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, a total of 109 employees on our Oncology/Immunology research and development team have M.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 29, 2021 | Name change | Name changed from Hutchison China MediTech Ltd to HUTCHMED (China) Ltd |
| Mar 18, 2016 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 4, 2016 | Listing | Registration of securities on an exchange (Form 8-A) |